MyFinsight
Home
Blog
About
Accrued expenses,
accrued collaboration...
$25,791K
(171.43%↑ Y/Y)
Net income
$25,432K
(-3.56%↓ Y/Y)
Proceeds from issuance of
class a ordinary...
$17,578K
(10.38%↑ Y/Y)
Share-based compensation
expense
$11,636K
(-30.00%↓ Y/Y)
Other long-term
liabilities
$8,612K
(15.77%↑ Y/Y)
Deferred income taxes
$2,661K
(-52.79%↓ Y/Y)
Inventory
-$2,211K
(-110.13%↓ Y/Y)
Non-cash lease expense
$1,011K
(-42.52%↓ Y/Y)
Depreciation and
amortization expense
$472K
(-32.86%↓ Y/Y)
Other long-term
assets
-$249K
(87.39%↑ Y/Y)
Net amortization of
premiums and accretion of...
-$93K
(-115.79%↓ Y/Y)
Net gain on disposal
of property and...
-$22K
(-191.67%↓ Y/Y)
Net cash provided by
operating activities
$47,195K
(-6.39%↓ Y/Y)
Net cash provided by
financing activities
$12,110K
(-10.07%↓ Y/Y)
Canceled cashflow
$30,995K
Canceled cashflow
$5,468K
Net increase in cash
and cash...
-$14,275K
(-268.82%↓ Y/Y)
Canceled cashflow
$59,305K
Proceeds from the
maturities of short-term...
$36,703K
(-50.82%↓ Y/Y)
Prepaid expenses and
other current assets
$18,572K
(52.29%↑ Y/Y)
Accounts payable
-$11,999K
(-271.61%↓ Y/Y)
Accounts receivable, net
$266K
(102.71%↑ Y/Y)
Operating lease
liabilities
-$158K
(91.11%↑ Y/Y)
Payments in connection
with ordinary shares...
$5,468K
(122.37%↑ Y/Y)
Net cash used in
investing activities
-$73,580K
(-32.76%↓ Y/Y)
Canceled cashflow
$36,703K
Purchases of short-term
investments
$109,620K
(-15.54%↓ Y/Y)
Purchases of property and
equipment
$663K
(151.14%↑ Y/Y)
Back
Back
Cash Flow
Kiniksa Pharmaceuticals International, plc (KNSA)
Kiniksa Pharmaceuticals International, plc (KNSA)
source: myfinsight.com